A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer.
Saved in:
| Title: | A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer. |
|---|---|
| Authors: | Finn RS; Division of Hematology/Oncology, David Geffen School of Medicine, University of California Los Angeles, 885 Tiverton Drive, Los Angeles, CA, 90095, USA., Rugo HS; City of Hope, Duarte Cancer Center, Duarte, CA, USA., Cortes J; International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain.; IOB Madrid, Institute of Oncology, Hospital Beata Maria Ana, Madrid, Spain., Loibl S; Center for Hematology and Oncology Bethanien, Frankfurt, Germany., Foley G; Pfizer Ltd, Surrey, UK., Gauthier E; Pfizer Inc, San Francisco, CA, USA., Wang Y; Pfizer Inc, New York, NY, USA., Kim S; Pfizer Inc, San Diego, CA, USA., Anders L; Pfizer Inc, San Diego, CA, USA., Slamon DJ; Division of Hematology/Oncology, David Geffen School of Medicine, University of California Los Angeles, 885 Tiverton Drive, Los Angeles, CA, 90095, USA. dslamon@mednet.ucla.edu. |
| Source: | Targeted oncology [Target Oncol] 2025 Nov; Vol. 20 (6), pp. 917-936. Date of Electronic Publication: 2025 Oct 14. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41087648 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Finn+RS%22">Finn RS</searchLink>; Division of Hematology/Oncology, David Geffen School of Medicine, University of California Los Angeles, 885 Tiverton Drive, Los Angeles, CA, 90095, USA.<br /><searchLink fieldCode="AU" term="%22Rugo+HS%22">Rugo HS</searchLink>; City of Hope, Duarte Cancer Center, Duarte, CA, USA.<br /><searchLink fieldCode="AU" term="%22Cortes+J%22">Cortes J</searchLink>; International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain.; IOB Madrid, Institute of Oncology, Hospital Beata Maria Ana, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Loibl+S%22">Loibl S</searchLink>; Center for Hematology and Oncology Bethanien, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Foley+G%22">Foley G</searchLink>; Pfizer Ltd, Surrey, UK.<br /><searchLink fieldCode="AU" term="%22Gauthier+E%22">Gauthier E</searchLink>; Pfizer Inc, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Pfizer Inc, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Kim+S%22">Kim S</searchLink>; Pfizer Inc, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Anders+L%22">Anders L</searchLink>; Pfizer Inc, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Slamon+DJ%22">Slamon DJ</searchLink>; Division of Hematology/Oncology, David Geffen School of Medicine, University of California Los Angeles, 885 Tiverton Drive, Los Angeles, CA, 90095, USA. dslamon@mednet.ucla.edu. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101270595%22">Targeted oncology</searchLink> [Target Oncol] 2025 Nov; Vol. 20 (6), pp. 917-936. <i>Date of Electronic Publication: </i>2025 Oct 14. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Review – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer-Verlag+France%22">Springer-Verlag France </searchLink><i>Country of Publication: </i>France <i>NLM ID: </i>101270595 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1776-260X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217762596%22">17762596 </searchLink><i>NLM ISO Abbreviation: </i>Target Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41087648 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s11523-025-01175-z Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 917 Titles: – TitleFull: A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Finn RS – PersonEntity: Name: NameFull: Rugo HS – PersonEntity: Name: NameFull: Cortes J – PersonEntity: Name: NameFull: Loibl S – PersonEntity: Name: NameFull: Foley G – PersonEntity: Name: NameFull: Gauthier E – PersonEntity: Name: NameFull: Wang Y – PersonEntity: Name: NameFull: Kim S – PersonEntity: Name: NameFull: Anders L – PersonEntity: Name: NameFull: Slamon DJ IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 11 Text: 2025 Nov Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1776-260X Numbering: – Type: volume Value: 20 – Type: issue Value: 6 Titles: – TitleFull: Targeted oncology Type: main |
| ResultId | 1 |
